Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Xiaoming Zhong, Jianqiong Yang, Hongyan Liu, Zhiwen Yang & Ping Luo. (2023) Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application. Drug Delivery 30:1.
Read now
Read now
Raj J. Ahiwale, Bothiraja Chellampillai & Atmaram P. Pawar. (2022) Investigation of novel sorafenib tosylate loaded biomaterial based nano-cochleates dispersion system for treatment of hepatocellular carcinoma. Journal of Dispersion Science and Technology 43:10, pages 1568-1586.
Read now
Read now
Min Liu, Meiwan Chen & Zhiwen Yang. (2017) Design of amphotericin B oral formulation for antifungal therapy. Drug Delivery 24:1, pages 1-9.
Read now
Read now
Zhiwen Yang, Meiwan Chen, Muhua Yang, Jian Chen, Weijun Fang & Ping Xu. (2014) Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection. International Journal of Nanomedicine 9, pages 327-336.
Read now
Read now
Fady Ibrahim, Pavel Gershkovich, Olena Sivak, Ellen K. Wasan & Kishor M. Wasan. (2013) Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats. Drug Development and Industrial Pharmacy 39:9, pages 1277-1283.
Read now
Read now
Sheila J. Thornton, Kishor M. Wasan, Anna Piecuch, Larry L D. Lynd & Ellen K. Wasan. (2010) Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. Drug Development and Industrial Pharmacy 36:11, pages 1312-1319.
Read now
Read now
Pore Vandana Sudhir, Deshpande Sunita Ranjan & Aher Nilkanth Ganpat. (2010) Antifungal agents, WO2009025733. Expert Opinion on Therapeutic Patents 20:1, pages 137-143.
Read now
Read now
Articles from other publishers (31)
Ellen Wasan, Tavonga Mandava, Pablo Crespo-Moran, Adrienne Nagy & Kishor M. Wasan. (2022) Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections. Pharmaceutics 14:11, pages 2316.
Crossref
Crossref
Mohamed G. El-Melegy, Hoda M. Eltaher, Ahmed Gaballah & Amal H. El-Kamel. (2021) Enhanced oral permeability of Trans-Resveratrol using nanocochleates for boosting anticancer efficacy; in-vitro and ex-vivo appraisal. European Journal of Pharmaceutics and Biopharmaceutics 168, pages 166-183.
Crossref
Crossref
Jawad ur Rehman, Imdad Ali, Salim Saifullah, Shafi Ullah, Muhammad Imran & Muhammad Raza Shah. (2021) Synthesis of quercetin based self-assembling supramolecular amphiphiles for amphotericin B delivery. Journal of Molecular Liquids 333, pages 115941.
Crossref
Crossref
Jiao Liu, Ping Leng & Yujun Liu. (2020) Oral drug delivery with nanoparticles into the gastrointestinal mucosa. Fundamental & Clinical Pharmacology 35:1, pages 86-96.
Crossref
Crossref
Wei Zhu, Wenquan Huang, Liping Ye, Yuehua Deng, Qiuling Xie & Yanbin Jiang. (2020) Facile preparation of succinylated-zein-ZIF-8 hybrid for enhanced stability and pH-responsive drug delivery. Chemical Engineering Science 228, pages 115981.
Crossref
Crossref
Kishor M. Wasan, Ellen K. Wasan & Peter Hnik. (2020) Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs. Antimicrobial Agents and Chemotherapy 64:11.
Crossref
Crossref
Kishor M. Wasan. (2020) Development of an Oral Amphotericin B Formulation as an Alternative Approach to Parenteral Amphotericin B Administration in the Treatment of Blood-Borne Fungal Infections. Current Pharmaceutical Design 26:14, pages 1521-1523.
Crossref
Crossref
Rana Khafagy, Sumit Gupta, Paolo Campisi & Valerie Waters. (2020) Treatment of localized mucormycosis using nasal amphotericin B irrigation in pediatric oncology. Pediatric Blood & Cancer.
Crossref
Crossref
Laura Machín, Beatriz Tamargo, Abel Piñón, Regla C. Atíes, Ramón Scull, William N. Setzer & Lianet Monzote. (2019) Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & Clemants (Amaranthaceae) Essential Oils Formulated in Nanocochleates against Leishmania amazonensis. Molecules 24:23, pages 4222.
Crossref
Crossref
Jinhua Zhang, Jie Ma, Yuanzhen Dong, Wenjie Zhao & Jun Feng. (2019) Synthesis and characterization of NH2-(AEEA)n-amphotericin B derivatives. The Journal of Antibiotics 72:4, pages 210-217.
Crossref
Crossref
Grace Cuddihy, Ellen Wasan, Yunyun Di & Kishor Wasan. (2019) The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?. Pharmaceutics 11:3, pages 99.
Crossref
Crossref
T.C. Moraes Moreira Carraro, C. Altmeyer, N. Maissar Khalil & R. Mara Mainardes. (2017) Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles. Journal de Mycologie Médicale 27:4, pages 519-529.
Crossref
Crossref
J. M. Falcón-González, G. Jiménez-Domínguez, I. Ortega-Blake & M. Carrillo-Tripp. (2017) Multi-Phase Solvation Model for Biological Membranes: Molecular Action Mechanism of Amphotericin B. Journal of Chemical Theory and Computation 13:7, pages 3388-3397.
Crossref
Crossref
Min Liu, Xiaoming Zhong & Zhiwen Yang. (2017) Chitosan functionalized nanocochleates for enhanced oral absorption of cyclosporine A. Scientific Reports 7:1.
Crossref
Crossref
Abhijit A. Date, Justin Hanes & Laura M. Ensign. (2016) Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. Journal of Controlled Release 240, pages 504-526.
Crossref
Crossref
Bushra T. AL-Quadeib, Mahasen A. Radwan, Lidija Siller, Benjamin Horrocks & Matthew C. Wright. (2015) Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization. Saudi Pharmaceutical Journal 23:3, pages 290-302.
Crossref
Crossref
A.C.O. Souza, A.L. Nascimento, N.M. de Vasconcelos, M.S. Jerônimo, I.M. Siqueira, L. R-Santos, D.O.S. Cintra, L.L. Fuscaldi, O.R. Pires Júnior, R. Titze-de-Almeida, M.F. Borin, S.N. Báo, O.P. Martins, V.N. Cardoso, S.O. Fernandes, M.R. Mortari, A.C. Tedesco, A.C. Amaral, M.S.S. Felipe & A.L. Bocca. (2015) Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles. European Journal of Medicinal Chemistry 95, pages 267-276.
Crossref
Crossref
Brad A. Haubrich, Ujjal K. Singha, Matthew B. Miller, Craigen R. Nes, Hosanna Anyatonwu, Laurence Lecordier, Presheet Patkar, David J. Leaver, Fernando Villalta, Benoit Vanhollebeke, Minu Chaudhuri & W. David Nes. (2015) Discovery of an ergosterol-signaling factor that regulates Trypanosoma brucei growth. Journal of Lipid Research 56:2, pages 331-341.
Crossref
Crossref
Neeradi Dinesh, Preet Kamal Kaur, Kayala Kambagiri Swamy & Sushma Singh. (2014) Mianserin, an antidepressant kills Leishmania donovani by depleting ergosterol levels. Experimental Parasitology 144, pages 84-90.
Crossref
Crossref
Leonid Kagan, Pavel Gershkovich, Kishor M. Wasan & Donald E. Mager. (2013) Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition. Pharmaceutical Research 31:1, pages 35-45.
Crossref
Crossref
Zhiwen Yang, Yinhe Tan, Meiwan Chen, Linghui Dian, Ziyun Shan, Xinsheng Peng & Chuanbin Wu. (2012) Development of Amphotericin B-Loaded Cubosomes Through the SolEmuls Technology for Enhancing the Oral Bioavailability. AAPS PharmSciTech 13:4, pages 1483-1491.
Crossref
Crossref
Sanyog Jain, Pankaj U. Valvi, Nitin K. Swarnakar & Kaushik Thanki. (2012) Gelatin Coated Hybrid Lipid Nanoparticles for Oral Delivery of Amphotericin B. Molecular Pharmaceutics 9:9, pages 2542-2553.
Crossref
Crossref
Fady Ibrahim, Pavel Gershkovich, Olena Sivak, Ellen K. Wasan & Kishor M. Wasan. (2012) Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. European Journal of Pharmaceutical Sciences 46:5, pages 323-328.
Crossref
Crossref
M. Alsaadi, J.L. Italia, A.B. Mullen, M.N.V. Ravi Kumar, A.A. Candlish, R.A.M. Williams, C.D. Shaw, F. Al Gawhari, G.H. Coombs, M. Wiese, A.H. Thomson, M. Puig-Sellart, J. Wallace, A. Sharp, L. Wheeler, P. Warn & K.C. Carter. (2012) The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. Journal of Controlled Release 160:3, pages 685-691.
Crossref
Crossref
Alexander V. LyubimovBenny M. Amore. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
39
.
Carlos G Leon, Jinkyung Lee, Karen Bartlett, Pavel Gershkovich, Ellen K Wasan, Jinying Zhao, John G Clement & Kishor M Wasan. (2011) In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines. Lipids in Health and Disease 10:1.
Crossref
Crossref
Olena Sivak, Pavel Gershkovich, Molly Lin, Ellen K Wasan, Jinying Zhao, David Owen, John G Clement & Kishor M Wasan. (2011) Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids in Health and Disease 10:1.
Crossref
Crossref
Qamar Zia, Mohammad Farzuddin, Mairaj Ahmad Ansari, Maroof Alam, Azmat Ali, Iqbal Ahmad & Mohammad Owais. 2010. Combating Fungal Infections. Combating Fungal Infections
485
528
.
Samusi A. Adediran, Timothy P. Day, Diptesh Sil, Matthew R. Kimbrell, Hemamali J. Warshakoon, Subbalakshmi S. Malladi & Sunil A. David. (2009) Synthesis of a Highly Water-Soluble Derivative of Amphotericin B with Attenuated Proinflammatory Activity. Molecular Pharmaceutics 6:5, pages 1582-1590.
Crossref
Crossref
Rafael Laniado-Laborín & Maria Noemí Cabrales-Vargas. (2009) Amphotericin B: side effects and toxicity. Revista Iberoamericana de Micología 26:4, pages 223-227.
Crossref
Crossref
Subhashis Chakraborty, Dali Shukla, Brahmeshwar Mishra & Sanjay Singh. (2009) Lipid – An emerging platform for oral delivery of drugs with poor bioavailability. European Journal of Pharmaceutics and Biopharmaceutics 73:1, pages 1-15.
Crossref
Crossref